Full-Time

Supervisor

Pharmaceutical Packaging

Posted on 9/11/2025

Viatris

Viatris

10,001+ employees

Global pharma selling generics and biosimilars

Compensation Overview

$55k - $105k/yr

Plattsburgh, NY, USA

In Person

Category
Medical, Clinical & Veterinary (1)
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
Requirements
  • A Bachelor's degree (or equivalent) and 2 - 4 years of relevant production experience is preferred. However, a combination of experience and/or education will be taken into consideration.
  • Must possess good communication, time management, organizational, interpersonal, leadership, writing and basic computer skills including Microsoft Word and Excel, Plateau, Trackwise and MTime.
  • Knowledge of industry practices and standards.
  • Solves routine problems of limited scope and complexity following established policies and procedures.
  • Ability to lift up to 50 pounds.
  • Ability to stoop, climb ladders, or stairs, stand or sit for extended periods of time.
  • Ability to wear a respirator.
  • Ability to hear an alarm.
  • Ability to identify small defects.
  • Ability to distinguish between colors.
Responsibilities
  • Ensure that assignments are completed on schedule following established policies and procedures. Guide and direct staff in production areas to assure compliance with the Production schedule.
  • Monitor production output and quality of work on the line versus established standards and initiate corrective actions as necessary working in conjunction with Production management, Quality Assurance, Maintenance, Engineering, etc.
  • Monitor and ensure proper equipment operation and all safety rules and guidelines are followed. Monitor work areas, ensuring appropriate cleanliness, orderly condition and cGMP compliance. Prepare and approve rooms and equipment for inspection. Perform room releases as necessary. Ensure that all equipment and room logs are current and accurate.
  • Coordinate and oversee the work of operators in other areas as necessary and act as a back-up to other supervisors or Manager as necessary.
  • Develop and perform training of personnel in Production operations, systems and cGMP compliance as necessary.
  • Record/Review data on Batch Production Records, In-Process Sheets, Log Books, and Time Sheets, deduction cards and other paperwork as required. Perform the required reconciliations associated with Controlled Substance manufactured lots. Perform final Production review of Batch Production Records prior to Quality review/approval. Obtain corrections as necessary and monitor error rates and initiate corrective actions to reduce errors.
  • Initiate events or investigations including collaboration with QA, identifying potential root causes and corrective and preventative actions to assure impact on quality is evaluated and minimized. Complete events and investigations within required timeframes including both procedural and production schedule based deadlines.
  • Initiate and complete procedural revisions and corresponding training modules assuring practice matches procedure and best practices are coordinated with all shifts.
  • Ensure all products produced or returned to inventory are properly labeled and monitor inventories.
  • Participate in the use of Pharmaceutical equipment for Process Development, Scale-up, and Process Validation batches and coordinate the training necessary to transfer new products/processes to commercial operations.
  • Provide input into requirements for new equipment or equipment upgrades and participate in the qualification/requalification of equipment.

Viatris provides access to medicines worldwide with a portfolio of branded drugs, generics, complex generics, and biosimilars across 165+ countries. Medicines are manufactured and distributed through its global supply chain and commercial network, serving cardiovascular, infectious diseases, immunology, and oncology. It leverages the legacy of Mylan and Upjohn to grow through both expanding its existing products and pursuing partnerships and acquisitions, driven by its broad portfolio and international reach. The goal is to improve patient health by expanding access to affordable medicines while pursuing sustainable operations and addressing public health challenges like non-communicable diseases.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hits $3.52B, up 8.1%, driven by Greater China demand.
  • Projects 5-6% revenue CAGR through 2030 with $11B cash for deployments.
  • UBS upgrades to Buy with $18 target on Inpefa launches and cost savings.

What critics are saying

  • FDA Indore warning letter slashes stock 15% on February 27, 2025.
  • Pfizer biosimilar captures 35% EU Lipitor share, cutting $1.2B sales.
  • FTC probes Mylan pay-for-delay deals, imposing $2B fine by 2028.

What makes Viatris unique

  • Viatris leverages Mylan-Upjohn merger for global generics and biosimilars portfolio.
  • Dominates complex generics in cardiovascular and immunology across 165 countries.
  • Advances pipeline with selatogrel and cenerimod for long-term cardiology growth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Company News

Yahoo Finance
Mar 23rd, 2026
Viatris shares surge 39.8% over past year, outpacing health care sector by 38.7%

Viatris, a global pharmaceutical company with a $15.2 billion market cap, has outperformed the broader healthcare sector despite recent headwinds. The Pennsylvania-based firm, which operates across 120 countries, has gained 39.8% over the past year, substantially ahead of the State Street Health Care Select Sector SPDR Fund's 1.1% decline. Shares have risen 10.7% over three months and 33.3% over six months, though they remain 19.9% below their 52-week high of $16.47. Viatris reported fourth-quarter revenue of $3.7 billion, up 5% year over year, with adjusted earnings per share of $0.57. Strong performance in branded drugs and emerging markets was offset by restructuring charges and pricing pressure in generics. Shares fell 5.2% following the announcement.

PR Newswire
Mar 23rd, 2026
Viatris wins approval for Effexor in Japan to treat generalised anxiety disorder

Viatris has received approval from Japan's Ministry of Health, Labour and Welfare for Effexor SR capsules to treat generalized anxiety disorder in adults, making it the first and only approved treatment for GAD in Japan. The drug was already approved in the country for major depressive disorder. The approval addresses a significant unmet need, as a recent study reported probable GAD prevalence of 7.6% in Japan's general population. The decision was based on a Phase 3 trial that demonstrated superior anxiolytic effects versus placebo at eight weeks, with all seven secondary endpoints met. Effexor was generally well tolerated with low discontinuation rates. Viatris' Japanese portfolio includes innovative products such as Spydia Nasal Spray, with several investigational therapies in development. Effexor is approved for GAD in over 80 countries worldwide.

PR Newswire
Mar 19th, 2026
Viatris targets $11B cash deployment through 2030 with 5-6% revenue growth

Viatris has outlined financial targets through 2030 at its investor event, projecting 5% to 6% total revenue compound annual growth and more than $3 billion in annual free cash flow by 2030. The pharmaceutical company's valuation at $1.45 billion reflects investor confidence in its strategic evolution. The Pittsburgh-based firm expects impactful near-term launches, including fast-acting meloxicam and a low-dose oestrogen patch in the US, alongside pitolisant and Effexor in Japan. Longer-term growth potential includes drug candidates selatogrel and cenerimod. Viatris anticipates over $11 billion in cash available for deployment through 2030, with approximately 50% allocated to business development. The company recently identified $650 million in cost savings over three years through an enterprise-wide strategic review.

Yahoo Finance
Mar 11th, 2026
Viatris shares surge 37.8% in six months, but analysts warn against buying despite cheap 5.8× P/E valuation

Viatris shares have surged 37.8% over the past six months, outpacing the S&P 500 by 34.7 percentage points, trading at $14.11. Despite the recent rally, analysts remain cautious about the pharmaceutical company's prospects. The company's fundamentals show concerning trends. Revenue grew at just 3.7% annually over the past five years, whilst earnings per share declined 9.8% annually during the same period, indicating deteriorating profitability. Most notably, Viatris posted a negative 2.6% five-year average return on invested capital, meaning management lost money whilst attempting business expansion. The stock currently trades at 5.8× forward price-to-earnings ratio. Analysts suggest the valuation appears optically cheap but warn of significant downside risk given the weak underlying fundamentals.

Yahoo Finance
Feb 26th, 2026
Viatris reports Q4 revenue of $3.7B, beating estimates by 5% with 10% growth in emerging markets

Viatris reported $3.7 billion in revenue for the quarter ended December 2025, representing a 5% year-over-year increase and beating the Zacks Consensus Estimate by 5.29%. Earnings per share reached $0.57, up from $0.54 a year ago and surpassing the consensus estimate of $0.52 by 9.62%. The pharmaceutical company showed strong performance across key segments. Greater China net sales rose 9.8% to $572.9 million, whilst Emerging Markets increased 10.1% to $564.7 million. Developed Markets generated $2.25 billion, up 4.7% year-over-year and exceeding analyst estimates. Shares of Viatris have gained 24% over the past month. The stock currently holds a Zacks Rank 3, suggesting it could perform in line with the broader market near term.

INACTIVE